GLP-1 companion food and nutrition market seen hitting $11.66 billion by 2030

The GLP-1 companion food and nutrition market is forecast to surge from $3.2 billion in 2025 to $11.66 billion by 2030 as obesity, diabetes and GLP-1 therapy use expand. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest.

Why it matters: - GLP-1 therapies are reshaping demand for foods and nutrition products designed to support weight loss and metabolic health. - The market's rapid growth reflects wider consumer and clinical focus on obesity, diabetes and personalized nutrition. - Companion products could become a larger part of the weight-management ecosystem as GLP-1 adoption expands.

What happened: - The Business Research Company projected the global GLP-1 companion food and nutrition market will rise from $3.2 billion in 2025 to $4.14 billion in 2026. - The market is forecast to reach $11.66 billion by 2030. - The company said the market is growing at a 29.2% CAGR from 2025 to 2026 and a 29.6% CAGR through 2030. - North America was the largest market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - GLP-1 companion food and nutrition refers to specialized dietary products and nutrition approaches designed to support GLP-1-based therapies used for weight and metabolic conditions. - These products aim to increase fullness, stabilize blood sugar and complement the physiological effects of GLP-1 hormones. - The company linked market growth to rising obesity and type 2 diabetes rates, broader use of pharmacological weight-management treatments, expansion of functional foods and dietary supplements, early clinical success with GLP-1 receptor agonist drugs, and stronger consumer interest in metabolic health. - Future growth is expected to come from wider GLP-1 therapy adoption, personalized nutrition, digital health and nutrition tracking, food-tech and biotechnology integration, and preventive healthcare programs. - The report highlighted personalized metabolic nutrition strategies, satiety-focused functional foods, low-glycemic meal systems, microbiome-oriented dietary interventions and protein-enhanced companion diets as key trends. - The company pointed to UK data showing 64.5% of adults in England were overweight or living with obesity in 2023-2024, up from 64.0% the year before. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics, and updated graphics and tables. - Download a free sample of the report - View the full report

Between the lines: - The forecast suggests GLP-1 drugs are creating spillover demand in adjacent consumer health categories, not just pharmaceuticals. - The emphasis on protein, fiber, satiety and glucose control signals a market moving toward products that solve therapy side effects and support adherence. - Regional growth patterns suggest mature demand in North America and faster adoption potential in emerging and health-focused Asia-Pacific markets.

What's next: - The market's trajectory will likely track how quickly GLP-1 therapies spread beyond early adopters into broader obesity and diabetes treatment. - Product innovation should center on personalized diets, low-glycemic formulations and nutrient-dense options that help preserve muscle mass. - More companies are likely to target the category as nutrition, digital health and biotech offerings converge.